Alkem launches Perampil (Perampanel Tablets)

Alkem Laboratories announced the launch of Perampil (Perampanel) tablets 2 mg/4 mg/6 mg for epilepsy treatment in India. Alkem has launched Perampil, at 2 mg – Rs 49/strip of 7 tablets, 4 mg – Rs 180/strip of 15 tablets and 6 mg – Rs 300/strip of 15 tablets.

Alkem had also launched Brivasure (Brivaracetam) tablets in March 2021 for the adjunctive management of partial onset seizure with or without secondary generalization.

The drug, Perampanel, has been approved by the Drugs Controller General of India (DCGI), as adjunctive therapy in the treatment of partial onset seizures in patients with epilepsy aged 4 years and older and also as adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in patients with epilepsy aged 12 years and older.